Programme Lead

James is an Honorary Consultant in Medical Oncology at Cambridge University Hospitals NHS Foundation Trust, and Clinical Senior Research Associate at the University of Cambridge. He specialises in the management of kidney cancer; his primary interest is in understanding how the tumour microenvironment influences the response to treatment and how this might inform better therapies. He is the translational science lead at the Cambridge Cancer Centre Urological Malignancies Virtual Institute. 

​

He is the scientific lead for several innovative clinical studies in kidney cancer, including the WIRE trial investigating novel treatments in the neoadjuvant setting for kidney cancer. These trials have an embedded translational research programme, to gain a deep understanding of the effects of treatment in each patient. He is the chief investigator of the ARTIST study, a large translational study aiming to capture the whole natural history of kidney cancer. ARTIST has recruited over 750 patients to date. He is also involved in the RAMPART study, which assessed adjuvant treatment for kidney cancer, and MANIFEST, a national consortium study investigating response and toxicities of immunotherapy.

​

He completed his PhD on the immunology of pancreatic cancer and has also worked on melanoma in his postgraduate training. He is a Fellow of Christ’s College Cambridge, where he teaches second year pathology.